CA2924233C — Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
Assigned to Teikoku Pharma USA Inc · Expires 2018-10-23 · 8y expired
What this patent protects
The invention provides devices, kits and approaches for treating Attention Deficit Hyperactivity Disorder (ADHD), anxiety or insomnia, comprising a composition of the .alpha.2-adrenergic agonist, dexmedetomidine. Clinically, dexmedetomidine is used as a sedative and is parenteral…
USPTO Abstract
The invention provides devices, kits and approaches for treating Attention Deficit Hyperactivity Disorder (ADHD), anxiety or insomnia, comprising a composition of the .alpha.2-adrenergic agonist, dexmedetomidine. Clinically, dexmedetomidine is used as a sedative and is parenterally, intravenously or orally administered, thus requiring close supervision by healthcare professionals. Provided herein are select embodiments of transdermal delivery devices that are configured to maintain contact with a subject and comprise dexmedetomidine compositions that are formulated in a manner sufficient to deliver an amount of dexmedetomidine to the skin surface of the subject for treating ADHD, anxiety or insomnia.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.